Medical and Health Science Journal

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Volume 10
Issue 1
Online publication date 2012-03-22
Title Efficacy and safety of intra-arterial thrombolytic therapy for ischemic stroke
Author Abdurakhman Zakhidov, Shukhrat Mubarakov, Farruh Djalalov, Natalya Dadamyantc, Djasur Khusankhodjaev
Abstract Early well-timed selective inter-arterial thrombolytic therapy (IATT) performed within 3-6 hour treatment window seems to be a promising method for early recanalization of the occluded vessel in acute stroke patients. We have performed the clinical trial to demonstrate efficacy and safety of IATT with streptokinase as a thrombolytic agent in 22 acute stroke patients hospitalized at the Republican Research Center of Emergency Medicine (Tashkent, Uzbekistan). At admission among 22 acute stroke patients atherothrombotic (n=16) and cardioembolic (n=6) subtypes were determined by means of color duplex sonography, clinical routine transcranial Doppler ultrasound examination and echocardiography. Post-IATT assessment by Glasgow Coma Scale, NIHSS and Rankin Scale demonstrated complete or significant neurological improvement and high degree of recanalization (72.7%). in this category of patients. 
AHA/ASA Scientific Statement, 2005. Guidelines for the early management of patients with  ischemic stroke 2005, Guidelines Update. Retrieved 27.01.2012 at

Clark, W., 1999. “Recombinant Tissue - Type  Plasminogen Activator  (Alteplase) for Ischemic Stroke 3 to 5  Hours After Symptoms Onset. The ATLANTIS Study: A Randomized Controlled Trial,” JAMA, 282(21), pp.2019-26

European Stroke Initiative  Recommendations for stroke  Management  - Update,  2003. Cerebrovasc. Dis., Vol.16, pp.311-37

Furlan, A., Higashida, R., Wechsler, L. et al., 1999. “Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in acute cerebral thromboembolisms,” JAMA, 282(21), pp.2003-11

Hacke, W. et al., 1995. “Intravenous thrombolysis with  recombinant tissue plasminogen activator for acute ischemic stroke:  the European Cooperative Acute Stroke Study (ECASS),” JAMA, Vol.274, pp.1017-25

Hacke, W. et al., 1998. “Randomized double-blind  placebo-controlled  trial of  thrombolytic therapy  with intravenous  alteplase in acute  ischemic stroke  (ECASS II),” Lancet,  Vol.352, pp.1245-251

Hacke, W. et al., 2004. “Association of outcomes with early stroke  treatment: Pooled analysis of ATLANTIS, ECASS and NINDS  rt-PA  stroke trials,” Lancet, Vol.363, pp.768-74

Multicentre Acute Stroke Trial - Italy (MAST-I) Group, 1995. “Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial - Italy (Mast-I) Group,” Lancet, Vol.346 (8989), pp.1509-14

Multicentre Acute Stroke Trial - Europe Study Group, 1996. “Thrombolytic therapy with streptokinase in acute ischemic stroke, Multicentre Acute Stroke Trial - Europe Study Group,” N Engl J Med, Vol.335 (3), pp.145-50

Suslina, Z., Kistenev, B., Geraskina, K., Tanashyan, M., 1997. “Thrombolytic  therapy  for ischemic stroke (urokinase application experience),” Neurological Journal [Nevrologicheskiy Jurnal], in Russian, No.5, pp.20-24 

Yasaka, M., Chambers, B., Davis, S., Donnan, G., 1998. “Streptokinase in acute stroke: Effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group,” Neurology, Vol.50(3), pp.626-32

Keywords Acute stroke, intra-arterial thrombolytic therapy, streptokinase, treatment window
Pages 2-9
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Search in articles
Journal Published articles
MHSJ 940
Journal Hits
MHSJ 2306020
Journal Downloads
MHSJ 17101
Total users online -